SV2003000603A - Compuestos con nucleos heterociclico-hidroximino- fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso caso no. 0089-01-sv - Google Patents
Compuestos con nucleos heterociclico-hidroximino- fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso caso no. 0089-01-svInfo
- Publication number
- SV2003000603A SV2003000603A SV2001000603A SV2001000603A SV2003000603A SV 2003000603 A SV2003000603 A SV 2003000603A SV 2001000603 A SV2001000603 A SV 2001000603A SV 2001000603 A SV2001000603 A SV 2001000603A SV 2003000603 A SV2003000603 A SV 2003000603A
- Authority
- SV
- El Salvador
- Prior art keywords
- compounds
- pharmaceutical compositions
- heterociclic
- hydroximine
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE DESCRIBEN LOS COMPUESTOS CON NUCLEOS HETEROCICLICOS-HIDROXILIMINO-FLUORENO QUE MODULAN Y/O INHIBEN LA ACTIVIDAD DE LAS PROTEINAS CINASAS. ESTOS COMPUESTOS Y LAS COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SON CAPACES DE MEDIR LA TRANSDUCCION DE LA SEÑAL DE LA TIROSINA CINASA PARA MODULAR Y/O INHIBIR LA PROLIFERACION DE LAS CELULAS INDECEABLES. LA INVENCION TAMBIEN SE DIRIGE AL USO TERAPEUTICO O PROFILACTICO DE LAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS COMPUESTOS, PARA EL TRATAMIENTO DEL CANCER Y LAS OTRAS ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS Y /O PROLIFERACION CELULAR INDESEABLE, TALES COMO LA RETINOPATIA DIABETICA, EL GLAUCOMA NEOVASCULAR, LA ARTRITIS REUMATOIDES Y LA SORIASIS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22480500P | 2000-08-18 | 2000-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2003000603A true SV2003000603A (es) | 2003-01-13 |
Family
ID=22842288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2001000603A SV2003000603A (es) | 2000-08-18 | 2001-08-17 | Compuestos con nucleos heterociclico-hidroximino- fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso caso no. 0089-01-sv |
Country Status (16)
Country | Link |
---|---|
US (1) | US6462060B2 (es) |
EP (1) | EP1309563B1 (es) |
JP (1) | JP2004506720A (es) |
AR (1) | AR032891A1 (es) |
AT (1) | ATE295354T1 (es) |
AU (1) | AU2001279090A1 (es) |
BR (1) | BR0113258A (es) |
CA (1) | CA2411924A1 (es) |
DE (1) | DE60110802T2 (es) |
ES (1) | ES2238463T3 (es) |
GT (1) | GT200100170A (es) |
MX (1) | MXPA03001452A (es) |
PA (1) | PA8525701A1 (es) |
PE (1) | PE20020289A1 (es) |
SV (1) | SV2003000603A (es) |
WO (1) | WO2002016326A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
AU2002364051A1 (en) * | 2002-01-24 | 2003-09-02 | Children's Medical Center Corporation | Anti-cancer combination and use thereof |
DE602004032370D1 (de) * | 2003-10-16 | 2011-06-01 | Imclone Llc | Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür |
AU2005308539A1 (en) * | 2004-10-06 | 2006-06-01 | Tiltan Pharma Ltd | Method and composition for enhancing anti-angiogenic therapy |
JP5117374B2 (ja) | 2005-03-29 | 2013-01-16 | イコス・コーポレイション | Chk1阻害に有用なヘテロアリール尿素誘導体 |
WO2007026720A1 (ja) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | 縮環ピラゾール誘導体 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
ES2219670T3 (es) | 1994-11-10 | 2004-12-01 | Millennium Pharmaceuticals, Inc. | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. |
US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
IL126873A (en) * | 1996-05-30 | 2005-09-25 | Aventis Pharma Inc | Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors |
GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
JP2001518501A (ja) | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | インデノ[1,2−c]−、ナフト[1,2−c]−およびベンゾ[6,7]シクロへプタ[1,2−c]ピラゾール誘導体 |
DE69835241T2 (de) | 1997-10-27 | 2007-05-31 | Agouron Pharmaceuticals, Inc., La Jolla | 4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen |
DE69837282T2 (de) | 1997-12-13 | 2007-11-08 | Bristol-Myers Squibb Co. | VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER |
HUP0100931A3 (en) | 1998-02-26 | 2002-08-28 | Aventis Pharma Inc | 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
DE69940951D1 (de) | 1998-04-21 | 2009-07-16 | Bristol Myers Squibb Pharma Co | Nd wachstumshemmende mittel |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
ES2270612T3 (es) | 1998-08-29 | 2007-04-01 | Astrazeneca Ab | Compuestos de pirimidina. |
ES2252972T3 (es) * | 1998-09-08 | 2006-05-16 | Agouron Pharmaceuticals, Inc. | Modificaciones de la proteina vegfr-2 y procedimiento de uso. |
JP2003517447A (ja) * | 1998-11-06 | 2003-05-27 | ビーエーエスエフ アクチェンゲゼルシャフト | 三環式ピラゾール誘導体 |
-
2001
- 2001-07-31 DE DE60110802T patent/DE60110802T2/de not_active Expired - Fee Related
- 2001-07-31 JP JP2002521202A patent/JP2004506720A/ja not_active Withdrawn
- 2001-07-31 ES ES01957334T patent/ES2238463T3/es not_active Expired - Lifetime
- 2001-07-31 AU AU2001279090A patent/AU2001279090A1/en not_active Abandoned
- 2001-07-31 CA CA002411924A patent/CA2411924A1/en not_active Abandoned
- 2001-07-31 BR BR0113258-0A patent/BR0113258A/pt not_active IP Right Cessation
- 2001-07-31 MX MXPA03001452A patent/MXPA03001452A/es active IP Right Grant
- 2001-07-31 EP EP01957334A patent/EP1309563B1/en not_active Expired - Lifetime
- 2001-07-31 AT AT01957334T patent/ATE295354T1/de not_active IP Right Cessation
- 2001-07-31 WO PCT/US2001/023897 patent/WO2002016326A1/en active IP Right Grant
- 2001-08-14 PE PE2001000808A patent/PE20020289A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103906A patent/AR032891A1/es unknown
- 2001-08-16 US US09/930,255 patent/US6462060B2/en not_active Expired - Fee Related
- 2001-08-17 GT GT200100170A patent/GT200100170A/es unknown
- 2001-08-17 PA PA20018525701A patent/PA8525701A1/es unknown
- 2001-08-17 SV SV2001000603A patent/SV2003000603A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ATE295354T1 (de) | 2005-05-15 |
AR032891A1 (es) | 2003-12-03 |
PE20020289A1 (es) | 2002-05-27 |
US6462060B2 (en) | 2002-10-08 |
WO2002016326A1 (en) | 2002-02-28 |
DE60110802D1 (de) | 2005-06-16 |
MXPA03001452A (es) | 2004-05-04 |
US20020049238A1 (en) | 2002-04-25 |
BR0113258A (pt) | 2003-07-15 |
EP1309563A1 (en) | 2003-05-14 |
ES2238463T3 (es) | 2005-09-01 |
EP1309563B1 (en) | 2005-05-11 |
JP2004506720A (ja) | 2004-03-04 |
PA8525701A1 (es) | 2002-04-25 |
AU2001279090A1 (en) | 2002-03-04 |
GT200100170A (es) | 2002-05-16 |
CA2411924A1 (en) | 2002-02-28 |
DE60110802T2 (de) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200100014A (es) | Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo. | |
DOP2001000120A (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar e inhibir la proliferación celular | |
UY26190A1 (es) | Compuestos de tiazol y composiciones farmacéuticas para inhibir a las proteinquinasas y métodos para su utilización | |
GT200400136A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibirlaproliferacion celular. | |
PA8592901A1 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso | |
PA8608201A1 (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular | |
PA8498001A1 (es) | Compuestos de indazole y composiciones farmaceuticas para la inhibicion de proteina kinasa, y metodos para su uso | |
AR007856A1 (es) | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina, quinasa, sus metodos de prepraracion, intermediarios, uso en medicina ycomposiciones farmaceuticas que los contienen | |
AR007855A1 (es) | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen | |
SV2003001148A (es) | Derivados de benzamida tiazol y composciones farmaceuticas para inhibir la proliferacion de celulas, y metodos para su utilizacion ref. no.0097-01-sv | |
ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
ATE267200T1 (de) | Bicyclische kinase inhibitoren | |
GT200100061A (es) | Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas. | |
PA8577501A1 (es) | Inhibidores de quinasas | |
CR20120009A (es) | 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728) | |
HK1051691A1 (en) | Hydroxylstilbenes and stilbene derivatives and analogues of anti-inflammatory and psoriasis treatment and protein kinase inhibition | |
UY27199A1 (es) | Nuevos compuestos antiinflamatorios de triazolopiridinas | |
SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
ES2194468T3 (es) | Uso de derivados del bisindol indigoide para la fabricacion de un medicamento para inhibir quinasas dependientes de ciclinas. | |
AR018201A1 (es) | Compuesto de mesilato de n-(3-etinilfenil)-6,7-bis-(2-metoxietoxi)-4-quinazolinamina, composiciones que los contienen y su uso de dichos compuestos para la preparacion de medicamentos. | |
ES2058306T3 (es) | Tetralinas substituidas, cromanos y compuestos relacionados en el tratamiento del asma, artritis y enfermedades relacionadas. | |
UY26877A1 (es) | Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes | |
BR0304963A (pt) | Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças | |
SV2003000603A (es) | Compuestos con nucleos heterociclico-hidroximino- fluoreno y las composiciones farmaceuticas para la inhibicion de las proteinas cinasas y los metodos para su uso caso no. 0089-01-sv | |
UY26498A1 (es) | Pirroles sustituidos |